Answers are grounded in this paper and cite their sources.
The impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) on pancreatic tissue acquisition has been so profound that the technique is regarded as a disruptive innovation [1]. However, EUS-FNA has two major limitations: the diagnostic performance is dependent on the availability of a cytopathologist to render rapid onsite evaluation and it doesn’t provide histology, which may be required to establish a conclusive diagnosis when FNA cytology alone is insufficient. The ProCore biopsy needle was developed to overcome these limitations. In this issue of the journal, two randomized trials compare the diagnostic performance of the ProCore and standard FNA needles for tissue acquisition in solid pancreatic mass lesions [2] [3].
No takes yet. Share an insight, caveat, or question.
Holt et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: